Ultivue Secures $22 Million Series C Funding to Advance Commercialization of Cellular Biomarker Identification Technology

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 27, U.S. local time, biotechnology company Ultivue completed a $22 million Series C financing round. The proceeds from this round will be used to support the commercialization of the company’s cell identification technology and assist medical teams in researching human cells.

It is reported that this round of financing was led by Northpond Ventures, with participation from ARCH Venture Partners, 6 Dimensions Capital, and Applied Ventures.

Ultivue, founded in 2015 by David R. Walt, Peng Yin, and Ralf Jungmann, is headquartered in Massachusetts, USA, and specializes in research on tissue marker identification and quantitative bioanalysis.

Ultivue’s UltiMapper series of products is primarily used for the identification of intracellular biomarkers, aiding in the detection and treatment of various diseases.

The UltiMapper I/O T-act Kit can be used to analyze the potential of T-cell activation-induced cell autonomous inactivation mechanisms. The kit contains all reagents required for staining and imaging CD3, granzyme B, Ki67, panCK/SOX10, as well as nuclear counterstains. During cell analysis, researchers can use the tools provided in the kit to assess multiple parameters, including T-cell-induced cell proliferation, cytotoxic cell generation, tumor cell mortality, and potential proliferation indices. By analyzing the relevant data, the role of T cells in immune responses can be investigated.

UltiMapper I/O PD-L1 Kit is primarily used to analyze tumor cell activity and supports patient self-administration under the guidance of instructions. The kit includes all staining and imaging reagents, such as CD8, CD68, PD-L1, panCK/Sox10, and nuclear counterstains. For cancer patients, malignant tumors exhibit significantly higher activity than benign ones. Patients can use the kit to measure indicators such as T-cell activity, the proportion of cytotoxic cells, and the number of inflammatory factors at the disease site, thereby analyzing tumor activity and seeking timely medical diagnosis and treatment at healthcare institutions.

Northpond Ventures, established in 2018, is a venture capital firm headquartered in Bethesda, Maryland, USA. The firm’s investment activities are primarily focused on life sciences, medical technology, and healthcare-related industries.

ARCH Venture Partners, founded in 1986, is a venture capital firm primarily focused on investments in the healthcare and clean energy sectors. The firm has invested in more than 120 companies to date and manages a total of $1.9 billion in funds.

6 Dimensions Capital is an investment firm focused on the healthcare and medical sectors, formed in May 2017 through the merger of Tonghe Capital and Yucheng Capital. The firm covers both the Chinese and U.S. markets and manages RMB 10 billion in assets, making it one of the largest investment institutions in the industry.

Applied Ventures, established in 2006, is a venture capital firm that primarily invests in early-stage technology companies poised for high growth and superior returns. Applied Ventures’ investments help deliver innovative technologies to Applied Materials’ core business and stimulate growth in the applications of semiconductors, displays, solar photovoltaics, and related products and services.

(Compiled by Liu Yujing)